[Skip to Navigation]
June 1965

Immunologic Competence of Patients With Psoriasis Receiving Cytotoxic Drug Therapy

Author Affiliations


From the Division of Dermatology, Department of Medicine, University of California School of Medicine. Associate Professor of Dermatology (Dr. Epstein), Assistant Professor of Dermatology (Dr. Maibach).

Arch Dermatol. 1965;91(6):599-606. doi:10.1001/archderm.1965.01600120031006

Patients with psoriasis receiving cytotoxic drug therapy and appropriate control subjects were exposed to (1) sensitizing doses of delayed allergens, dinitrochlorobenzene (DNCB), and paranitrosodimethylaniline (NDMA); (2) evocative patches of pentadecylcatechol (PDC); and (3) immunizing doses of a plague vaccine. Psoriatic patients so treated were very difficult to sensitize to DNCB and NDMA, reacted normally to PDC, and generally failed to give a primary or a secondary immune response to plague antigen.

Add or change institution